.

Deeper Knowledge, Faster

  • Find suppliers and generic API sources
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Cantor Fitzgerald
Fish and Richardson
Medtronic
Cipla
Baxter
Farmers Insurance
Julphar
UBS
Teva
Chinese Patent Office

Generated: June 28, 2017

DrugPatentWatch Database Preview

Dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir and what is the scope of dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir freedom to operate?

Dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir
is the generic ingredient in one branded drug marketed by Abbvie Inc and is included in one NDA. There are eighteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir has four hundred and fifty-nine patent family members in fifty-one countries.

One supplier is listed for this compound.

Summary for Generic Name: dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir

Tradenames:1
Patents:18
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Clinical Trials: see list3,129
Drug Prices:see low prices
DailyMed Link:dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abbvie Inc
VIEKIRA PAK (COPACKAGED)
dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir
TABLET, TABLET;ORAL206619-001Dec 19, 2014RXYesYes► Subscribe► Subscribe
Abbvie Inc
VIEKIRA PAK (COPACKAGED)
dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir
TABLET, TABLET;ORAL206619-001Dec 19, 2014RXYesYes8,492,386► Subscribe ► Subscribe
Abbvie Inc
VIEKIRA PAK (COPACKAGED)
dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir
TABLET, TABLET;ORAL206619-001Dec 19, 2014RXYesYes9,139,536► Subscribe ► Subscribe
Abbvie Inc
VIEKIRA PAK (COPACKAGED)
dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir
TABLET, TABLET;ORAL206619-001Dec 19, 2014RXYesYes7,364,752► SubscribeY ► Subscribe
Abbvie Inc
VIEKIRA PAK (COPACKAGED)
dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir
TABLET, TABLET;ORAL206619-001Dec 19, 2014RXYesYes8,268,349► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Abbvie Inc
VIEKIRA PAK (COPACKAGED)
dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir
TABLET, TABLET;ORAL206619-001Dec 19, 20146,037,157► Subscribe
Abbvie Inc
VIEKIRA PAK (COPACKAGED)
dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir
TABLET, TABLET;ORAL206619-001Dec 19, 20146,703,403► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,025,899Solid pharmaceutical dosage form► Subscribe
8,309,613Solid pharmaceutical dosage form► Subscribe
9,023,8782-iminobiotin formulations and uses thereof► Subscribe
8,193,367Polymorph of a pharmaceutical► Subscribe
9,586,978Anti-viral compounds► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir

Country Document Number Estimated Expiration
New Zealand599361► Subscribe
Cyprus1114356► Subscribe
China104193729► Subscribe
United Kingdom2506086► Subscribe
Hong Kong1184068► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: DASABUVIR SODIUM ; OMBITASVIR; PARITAPREVIR; RITONAVIR

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2015000039Germany► SubscribePRODUCT NAME: OMBITASVIR; REGISTRATION NO/DATE: EU/1/14/982 20150115
2015 00014Denmark► SubscribePRODUCT NAME: DASABUVIR OR A SALT THEREOF, INCLUDING DASABUVIR SODIUM MONOHYDRATE; REG. NO/DATE: EU/1/14/983 20150119
0729Netherlands► SubscribePRODUCT NAME: DASABUVIR OF ZOUT DAARVAN, WAARONDER DASABUVIR NATRIUMMONOHYDRAAT; REGISTRATION NO/DATE: EU/1/14/983 20150119
668Luxembourg► SubscribePRODUCT NAME: OMBITASVIR, OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE QUI EN DERIVE (VIEKIRAX R); FIRST REGISTRATION DATE: 20150119
2015011Lithuania► SubscribePRODUCT NAME: PARITAPREVIRUM; REGISTRATION NO/DATE: EU/1/14.982 20150115
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Fish and Richardson
Baxter
US Department of Justice
Teva
Chubb
Mallinckrodt
AstraZeneca
Dow
QuintilesIMS
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot